Latest news for Encision (OTC:ECIA) Stock

Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provide surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities. Maximum revenue is generated from the product segment.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

AVTX

AXDX

CBAY

ECIA

NFLX

US stock futures traded lower this morning after Netflix, Inc. (NASDAQ: NFLX) issued weak subscriber growth forecast for the first quarter. However, investors also focused on some notable insider trades.

4 Penny Stocks Insiders Are Buying: CymaBay Therapeutics, Avalo Therapeutics And More

Intraday Update

Movers

ACAD

AEIS

AGEN

AMGN

ANSS

APPS

ARWR

BLDP

BLDR

BOOT

BXMX

CABA

CABO

CBPX

CELG

CLLXF

CLNFF

CMRE

COHU

CORG

CRSP

DCPH

DOOR

DRNA

DXCM

EBMT

EPRT

EVRI

FCNCA

FRTA

FSBW

FTLF

FTNT

FWONA

FWONK

GAIN

GLAD

GLIBA

GLIBB

GLPI

GMRE

GRBK

HLIT

IMXI

INGXF

INMD

INTZ

IPHI

KDMN

KEYS

KLAC

KPTI

LITE

LSXMA

MBWM

MNRLF

MPAA

MPWR

MRVL

MSFT

MSTR

NBIX

NIOBF

NMRK

NVMI

NXPI

PARR

PODD

Stocks That Hit 52-Week Highs On Tuesday

Encision Inc

Encision GAAP EPS of -$0.01, revenue of $1.65M

Encision GAAP EPS of $0.00, revenue of $1.75M

Encision GAAP EPS of -$0.02, revenue of $1.56M

Encision GAAP EPS of -$0.03, revenue of $1.53M

Earnings

Press Releases

Encision Reports First Quarter Fiscal Year 2024 Results

Encision Reports Second Quarter Fiscal Year 2024 Results

Encision Reports Third Quarter Fiscal Year 2024 Results

Encision Reports Fourth Quarter Fiscal Year 2024 Results

Encision

Encision (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ECIA#OTC">ECIA</a>) reported quarterly losses of $(0.01) per share. The company reported $1.81 million in sales this quarter.

Encision Q4 EPS $(0.01), Sales $1.81M

US stock futures traded lower this morning after Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) issued weak subscriber growth forecast for the first quarter. However, investors also focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.

<h2>Avalo Therapeutics </h2>

<ul>
	<li>The Trade: Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) Director Steven Boyd <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 312,000 shares </a> at an average price of $0.88. To acquire these shares, it cost $274,486.28.</li>
	<li>What&rsquo;s Happening: Avalo Therapeutics recently reported Phase 1b results for AVTX-002 in moderate to severe Crohn&#39;s disease patients and presented additional program updates at the 2022 investor event.</li>
	<li>What Avalo Therapeutics Does: Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.</li>
</ul>

<h2>Encision </h2>

<ul>
	<li>The Trade: Encision Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ECIA#OTC">ECIA</a>) Director Robert Fries <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 5,000 shares </a> at an average price of $0.35. The insider spent $1,750.00 to buy those shares.</li>
	<li>What&rsquo;s Happening: The company&rsquo;s stock dropped around 4% over the previous month.</li>
	<li>What Encision Does: Encision Inc is a medical device company. It develops and markets technology that provides unprecedented outcomes and patient safety in minimally-invasive surgery.</li>
</ul>

<h2>Accelerate Diagnostics </h2>

<ul>
	<li>The Trade: Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) Director Jack Schuler <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 41,912 shares </a> at an average price of $3.94. To acquire these shares, it cost $165,133.28.</li>
	<li>What&rsquo;s Happening: Accelerate Diagnostics recently said preliminary Q4 sales and FY21 sales are expected to be below estimates.</li>
	<li>What Accelerate Diagnostics Does: Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm&#39;s core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic.</li>
</ul>

<h2>CymaBay Therapeutics </h2>

<ul>
	<li>The Trade: CymaBay Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAY#NASDAQ">CBAY</a>) Chief Medical Officer Dennis D Kim <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 20,000 shares </a> at an average price of $3.04. The insider spent $60,800.00 to buy those shares.</li>
	<li>What&rsquo;s Happening: The company&rsquo;s shares dropped around 35% over the past six months.</li>
	<li>What CymaBay Therapeutics Does: CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982.</li>
</ul>

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Encision

News

Latest news for Encision (OTC:ECIA) Stock

Thursday, June 22, 2023

Friday, January 21, 2022

Tuesday, March 24, 2020

Tuesday, November 12, 2019

Friday, June 27, 2014